The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer | BMC Immunology | Full Text

The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer | BMC Immunology | Full Text

The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer

Myeloid derived suppressor cells (MDSCs) present a significant obstacle to cancer immunotherapy because they dampen anti-tumor cytotoxic T cell responses. Previous groups, including our own, have reported on t...

Authors:Andrea J. Luker, Laura J. Graham, Timothy M. Smith Jr, Carmen Camarena, Matt P. Zellner, Jamie-Jean S. Gilmer, Sheela R. Damle, Daniel H. Conrad, Harry D. Bear and Rebecca K. Martin

Citation:BMC Immunology 2020 21:8

Content type:Research article

Published on: 27 February 2020

• ViewFull Text
 
• ViewPDF